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Background As treatments continue to progress, patients with advanced cancer are living longer. 
However, ongoing physical side-effects and psychosocial concerns can compromise quality of life 
(QoL). Patients and physicians increasingly look to the internet and other technologies to address 
diverse supportive needs encountered across this evolving cancer trajectory.  
Objectives 1. To examine the features and delivery of web and technological interventions supporting 
patients with advanced cancer. 2. To explore their efficacy relating to QoL and psychosocial well-being.  
Methods Relevant studies were identified through electronic database searches (Medline, PsychINFO, 
Embase, CINAHL, CENTRAL, Web of Science and Proquest) and handsearching. Findings were collated 
and explored through narrative synthesis.  
Results Of 5274 identified records, 37 articles were included. Interventions were evaluated within 
studies targeting advanced cancer (13) or encompassing all stages (24). Five subtypes emerged: 
Interactive Health Communication Applications (n=12), virtual programmes of support (n=11), 
symptom monitoring tools (n=8), communication conduits (n=3) and information websites (n=3). 
Modes of delivery ranged from self-management to clinically integrated. Support largely targeted 
psychosocial well-being, alongside symptom management and healthy living. Most studies (78%) 
evidenced varying degrees of efficacy through QoL and psychosocial measures. Intervention 
complexity made it challenging to distinguish the most effective components. Incomplete reporting 
limited risk of bias assessment.  
Conclusion Whilst complex and varied in their content, features and delivery, most interventions led 
to improvements in QoL or psychosocial well-being across the cancer trajectory. Ongoing 
development and evaluation of such innovations should specifically target patients requiring longer-
term support for later-stage cancer.  










What is already known?  
• Use of the internet and other technologies to provide support across the cancer trajectory has 
proliferated in recent years.  
• Reviews of evidence are limited by heterogeneity across studies and lack focus on advanced 
cancer.  
 
What are the new findings?  
• Diverse web and technological interventions, focused largely on psychosocial needs, provide 
self-management and expert-guided support in line with an identified model of delivery.  
• The vast majority confer efficacy related to QoL and psychosocial well-being. Most encompass 
all stages of cancer; few are exclusive to advanced cancer.  
 
What is their significance?  
Clinical  
• With ongoing progress in the treatment of advanced cancer, evidence-based interventions 
are needed to support patients’ QoL. Viable designs and modes of delivery exist to deliver 
tailored, accessible support via the internet and other technologies.  
Research 












The term ‘advanced’ describes the spread of cancer beyond the original tumour, either locally (stage 
III) or to distant regions of the body (‘metastatic’ or stage IV).1 Though a cure is not usually attainable, 
treatment can slow the progression of disease and control symptoms. As therapies targeting these 
later stages continue to progress, patients are living longer with advanced cancer.2 Yet, as the disease 
trajectory extends, supportive needs can become more complex and burdensome.3 Around half of all 
patients with cancer are now estimated to survive 10 years beyond diagnosis, many living with 
advanced stage disease.4 As such, cancer is increasingly conceptualised as a chronic disease, bringing 
distinct, long-term supportive care needs to those for whom it remains ‘incurable but treatable’.5 6 
Physical symptoms of cancer progression are frequently experienced alongside diverse side-effects of 
treatments past and present. Furthermore, psychological, social and spiritual implications of ongoing 
disease and uncertain prognosis are far-reaching and greatly affect patients’ quality of life (QoL).7   
In 2007, the UK’s Department of Health outlined services and support necessary for patients living 
with long-term conditions. Patient choice and collaboration were highlighted as key requirements 
within what was termed the  ‘Generic Choice Model’.8 Harley et al. later applied qualitative research 
methods to tailor this model to the chronic cancer context.6 Several of the overarching areas of 
support identified are increasingly delivered via the internet and technology. In particular, innovations 
supporting cancer patients’ psychological well-being, self-care and self-management have 
proliferated over recent decades, from discussion forums and online support groups, to health 
information websites, mobile applications and platforms facilitating symptom monitoring.9-11 With 
approximately 2.5 million people living with cancer in the UK, projected to rise to over 4 million by 
2030,12 cancer support services face ever-growing demand. Yet these technologies offer a viable 
alternative to in-person support, connecting patients to one another, as well as to clinical services and 
sources of expert support. For patients with advanced cancer, less frequent follow up and home-based 
treatments may limit contact with health services and professionals. Timely and accessible 
information and support, delivered via the internet and other technologies, has the potential to bridge 
this gap and to address what are widely reported to be unmet holistic support needs in this growing 
patient group.7 13 14 Indeed, the need for such remote technologies has been further heightened by 
the COVID-19 pandemic and its impact on cancer care delivery.15  
Previous reviews have explored web and technological innovations in the field of cancer support yet 
have generally lacked focus on the distinct supportive needs encountered in the advanced stages of 
disease. Insight is limited by heterogeneous evidence and populations, with calls for further research 
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in order to more clearly ascertain the efficacy of these interventions across the cancer survivorship 
trajectory.16-19   
 
AIM & OBJECTIVES 
 
Our aim is to address the overall research question, ‘Does the use of web and technological supportive 
interventions in advanced and metastatic cancer improve quality of life?’ 
The objectives of this systematic review are therefore to: 
1. Examine the design and delivery of web and technological interventions in the context of 
advanced cancer.  
2. Explore their efficacy in relation to patients’ QoL and other psychosocial outcomes, evaluated 




The study protocol was registered with PROSPERO (reference: CRD42018089153). Methodology 
followed Preferred Reporting Items for Systematic reviews and Meta Analyses (PRISMA) guidelines20 




Electronic database search 
 
A search for randomised and non-randomised controlled trials evaluating web and technological 
interventions in patients with advanced cancer was conducted in April 2018. Database specific 
searches were performed in MEDLINE, Embase, PsycInfo, CINAHL, Web of Science, Cochrane Register 
of Controlled Trials and ProQuest. Search terms combined medical subject headings (MeSH) and 
keywords relating to advanced cancer (e.g. advanced, stage III/IV, metastatic), web and technological 
platforms (e.g. internet, electronic, mobile) and types of intervention (e.g. programme, application, 
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tool). Restrictions on language or year of publication were not applied. An updated database search 
was conducted in February 2019.  




Electronic searches were supplemented by hand searching key journals in the field (Journal of Clinical 





The following inclusion criteria were developed using the ‘PICOS’ framework.22 
- Population: inclusive of adults (≥ 18 years) diagnosed with any advanced or metastatic cancer 
(stage III or IV).  
- Intervention: web or technological interventions designed to support patients with cancer.  
The term ‘technological’ refers to interventions harnessing technologies which may not 
necessarily be web-based. Symptom monitoring interventions needed to include some form 
of feedback to be regarded as supportive.  
- Comparison: between interventions (e.g. web-based versus face-to-face) or with usual care.   
- Outcome: efficacy of the intervention assessed (as a primary or secondary outcome) through 
measures relating to QoL (validated QoL measures, e.g. EORTC QLQ-C30, or other QoL-related 
psychosocial constructs, e.g. anxiety, distress, functional status etc.)  
- Study design: randomised controlled trials (RCTs) and non-randomised controlled trials.  
Studies exclusively targeting early stage cancers or patients receiving treatment with curative intent 







Data selection and extraction  
 
Preliminary screening of titles and abstracts was performed (stage one), followed by full-text review 
(stage two). A random sample (20%) was screened by the wider research team (F.K, C.H, K.A). 
Concordance was high, with over 98% agreement between reviewers. Differing decisions were 
discussed until consensus was reached. Papers with titles and abstracts referring to  ‘cancer survivors’, 
with no further details of staging, were reviewed in full to determine participant eligibility.  
A data collection form was adapted and piloted in Microsoft Excel, following guidance for the process 
of data extraction.21 This gathered data relating to study author, year & country of publication, study 
design, objective, sample size, study population, intervention period, description and delivery of the 
intervention, relevant outcome measures and results. 
 
Risk of bias  
 
Studies were critically appraised using a modified version of the Cochrane Collaboration’s risk of bias 
assessment tool for RCTs.23 This encompasses five domains of bias: selection, performance, detection, 
attrition and reporting. Each study was assessed for ‘high’, ‘low’ or ‘unclear’ risk of bias for each 
individual domain.   
 
Narrative synthesis  
 
Significant heterogeneity across interventions, study methods and outcome measures precluded 
meta-analysis. A narrative synthesis was therefore conducted, guided by methods outlined by Popay 
et al.24 The first stage involved gathering commonalities and distinctions across interventions. This 
allowed for the development of theory and categorisations relating to their features and delivery. A 
preliminary synthesis of interventions within their emerging subtypes then allowed us to explore 









Electronic database searches identified 5194 articles, with an additional 80 identified through hand-
searching. Following removal of duplicates, titles and abstracts of 3883 records were screened, with 
112 full text articles subsequently retrieved.    
In total, 37 studies (of 35 original interventions and 2 intervention adaptations) met the inclusion 
criteria.  Figure 1 outlines the screening process in full.  
 




Of the 37 included studies, 30 were full-scale RCTs and 7 were pilot or feasibility studies. The majority 
were conducted in the USA (54%) and Europe (35%). Results were illustrative of a rapidly emerging 
field, with 42% published between 2017 and 2019. Thirteen studies specifically evaluated 
interventions in patients with advanced cancer, whilst the remaining 24 were inclusive of early and 
late stage disease. Most studies included either breast cancer at all stages (n=10) or a mixed 
population of many disease sites (n=15). Others targeted lung (n=3), ovarian (n=2), prostate (n=1), 
neurological (n=1), haematological (n=1), colorectal (n=1) and breast & prostate (n=1) cancers. The 
remaining (n=2) focused exclusively on metastatic breast cancer.  
 
Online supplemental table S1 provides an overview of included studies and interventions evaluated.  
 
 
Risk of bias assessment  
 
Full results of the risk of bias assessment are detailed within online supplemental table S2. Pattern of 
risk varied across studies, though high risk of detection bias was widespread (78% of studies). This 
relates to the vast majority of QoL and psychosocial outcome measures in the trials evaluated being 
self-reported, as well as challenges relating to blinding in interventions of this nature. Lowest risk was 
observed for selection bias (86% of studies describing random sequence generation, 62% 
demonstrating allocation concealment). Crucially, risk of bias assessment was limited by the level of 
detail reported; insufficient information resulted in ‘unclear’ judgements. To provide a more complete 
overview of the evidence base, articles were not excluded from the review based on this assessment. 
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However, this risk (whether high or unclear) and associated study limitations must be considered 
when drawing inferences from their results. 
 
 
Categorising interventions  
 
Intervention subtypes  
 
By collating descriptions of interventions’ features and delivery, shared characteristics became 
apparent. Drawing on literature in the wider field, alongside the articles under review, definitions were 
assigned to five distinct intervention subtypes (table 1).  
Some of these definitions mirror those used across the evidence base e.g. ‘information websites’ and 
‘symptom monitoring tools.’25 26 The term ‘Interactive Health Communication Applications’ (IHCAs) 
was outlined by the Science Panel on Interactive Health Communication over two decades ago and 
has since proliferated across the field of chronic disease management.27 28 Other definitions were 
developed to describe the shared purpose of related interventions, where appropriate terms had not 




















Further categories were assigned to describe the overarching focus of the interventions (identified in 
online supplemental table S1). These were defined by grouping together those targeting similar 
supportive needs, guided by areas of support discussed in the wider literature.7 29 
➢ ‘Psychosocial’ (PS): Targeting psychological behaviours and symptoms or encouraging socio-
emotional well-being through shared experience and communication. This was an overarching 
focus across all subtypes.   
➢ ‘Symptom management’ (S): Focusing on the monitoring and management of predominantly 
physical symptoms and side-effects.  


























Computer-based (usually web-enabled) 
package of information and support, 
bringing together health information with 
a range of other features, encompassing 






Structured programme of support (e.g. 
modular or a set number of sessions) 
providing education and/or training, 
delivered via an online platform or mobile 





Web based tool or mobile application 
allowing users to self-report occurrence 
and severity of symptoms, for the 
purposes of self and/or clinician 
monitoring, usually generating a written or 





Supportive resource acting as a channel 
for communication, allowing users to 
reach out and receive advice and guidance 
in the home setting from peers or from 
professionals such as clinical nurse 




Web page(s) providing 
information/content and links on a single 
platform, in the absence of additional 




➢ ‘Health & lifestyle’ (H/L): Encompassing aspects of healthy living more generally, such as diet 
and exercise. 
Many interventions encompassed more than one focus, most notably the IHCAs.  
 
Mode of delivery    
 
Interventions could also be distinguished according to aspects of their delivery:  
(i) the level of patient versus health professional or other expert involvement; 
(ii) the extent to which interventions were integrated within the patients’ usual care pathway.  
From these characteristics, various modes of delivery were described. ‘Self-management’ and 
‘clinically integrated’ are terms used to describe what are often contrasting approaches to delivering 
patient support. However, approaches of the reviewed interventions were much more nuanced. 
Focusing on the patient and the professional (healthcare or otherwise) as key participators, their 
varying level of involvement was used as the basis for describing different modes of delivery. 
‘Supported self-management’, a term increasingly encountered in cancer survivorship research,30 was 
adopted to describe a ‘middle ground’ between patients independently self-managing and experts 
having a key role in facilitation. ‘Professionally delivered’ acknowledged significant expert input which 
was distinct from patients’ usual care.  
To illustrate our developing theory, we brought these modes together within a model of intervention 
delivery (figure 2). Level of patient independence in self-management increases with progression up 
the pyramid. Conversely, health professionals are more closely involved in the delivery of 
interventions further down the pyramid. 
Some interventions traverse the pyramid, applying several modes of delivery in the support they 
provide.  
 







Intervention features and delivery   
 
Interactive health communication applications (IHCAs)  
 
A wide range of IHCAs were evaluated across 12 RCTs. Half of these targeted patients with advanced 
cancer;31-36 the remaining had diverse cancer patient populations. Their multi-faceted nature meant 
that most encompassed more than one focus. Psychosocial and symptom-management support were 
frequently integrated, with more general health and lifestyle support featuring to a lesser extent. 
The majority included health information and signposting,31-33 35-40 some providing self-management 
guidance as a separate focus (S).31 33 35 38 39 41 One intervention presented topics at varying levels of 
detail, allowing users to access information according to their needs.35 The ‘Surviving and Thriving with 
Cancer’ intervention delivered a weekly education course, encouraging both physical and 
psychological health behaviour change (H/L, PS).42 In some cases, self-management information was 
accompanied by facilities for varying degrees of physical and psychological symptom and status 
monitoring (S/PS).31-35 38-40 Uniquely, ‘ILOVEBREAST’ used a mobile gaming format to support 
chemotherapy side-effect self-management, integrating health information with features for social 
networking and self-assessment (S, H/L).34  
Decision support was another key component of several IHCAs. These provided users with a range of 
holistic and disease-specific information, supporting them to make decisions about their care needs.32 
35 36 40   
The majority facilitated user-user communication via forums,35 38 39 41 a chat room31 and discussion 
groups.32 36 37 40 Additionally, many permitted patients to communicate with and receive support from 
professionals.32 33 35 38-41 Further interactive components included audio visual self-management 
resources31 40 and online diaries.31 35 38 39 The use of patient ‘stories’ to encourage learning through 
shared experience was also central to several interventions.33 36 
Within the model of intervention delivery (figure 2), four IHCAs were  classified as ‘supported self-
management’, giving users the option to contact experts outside their healthcare team.33 38 40 41 
‘Supported self-management’ and ‘professional delivery’ were combined in two IHCAs, both 
encouraging self-management with an element of expert guidance as a core feature.37 42 Others 
represented purely self-management tools.34-36 39 The remaining interventions incorporated clinical 
integration via follow-up with a care co-ordinator31 and through an in-built symptom monitoring 
feature which sent reports and alerts to clinicians.32 
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Virtual programmes of support   
 
Few of the virtual programmes of support (2/11) were specific to advanced cancer.43 44 The majority 
applied cognitive behavioural therapy (CBT) principles, addressing symptoms such as stress, pain, 
insomnia and anxiety through guided online courses and exercises (PS).43-49 Mindfulness and stress-
management principles were also incorporated.44 45 49 50 Another programme facilitated self-help 
through problem solving therapeutic principles.51  Contrasting with the predominantly psychosocial 
focus, ‘e-CUIDATE’, a rehabilitative healthy lifestyle programme for breast cancer survivors, delivered 
online health information and tailored exercise sessions (H/L).52 Another programme included physical 
symptom monitoring (S), with users self-reporting pain during self-guided CBT.47  
Across programmes, patients were guided to work through modules47-49 51, chapters45 or sessions over 
a set number of weeks.43 44 46 50 52 53  A range of modalities were used to deliver programmes via online 
platforms and mobile applications, including videos and graphics, 43 45 47-49 53 exercises and 
worksheets,43-53 audio content44 49 53 and vignettes.45 46 48 Some offered elements of personalisation, 
tailoring content to users’ responses and needs.47 48 51 52 Several involved virtual group sessions, 
guiding development of self-management skills such as stress reduction, relaxation and mindfulness.44 
50 Numerous programmes included interactive elements, connecting users to professionals44-46 49-52 
and to each other45 for support or feedback. Another applied an alternative approach, integrating 
videos displaying simulated patient-therapist interactions.43 
The extent to which patients were supported to self-manage differed, with programmes incorporating 
various approaches outlined in the model of intervention delivery (figure 2). Some were professionally 
delivered44-46 50 52 whilst others encouraged more independent self-management, either purely 
patient-led,43 47 48 53 or with  optional access to professional support.49 51 
 
Symptom monitoring tools  
  
The symptom monitoring tools supported patients to manage predominantly physical aspects of 
health and treatment (S), with 4/8 specific to  advanced cancer.54-57 The remaining encompassed all 
stages.58-61  
Some used hand-held digital devices,54 58 tablet computers56 59 and web-applications55 60 to enable at-
home symptom reporting. Others harnessed similar technology to support shared symptom 
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monitoring during inpatient and outpatient clinical encounters.57 60 61 Several tools combined self-
reported symptoms with clinical data such as weight,54 55 height, performance status and 
medications.54 Two interventions supplemented objective self-report scores with additional patient 
input, in the form of free text comments 55 and a diary feature.60  
There was significant variability in the depth of symptom monitoring permitted, in terms of  number 
of symptoms and specified reporting frequency. Several involved weekly completions,54 55 58 whilst 
others were aligned with clinical encounters.56 57 59 61 One tool also encouraged patients to report 
symptoms in line with their needs.60 Extent of monitoring ranged from between 9-24 specified 
symptoms or issues,54-57 59  to full-length health/QoL questionnaires and inventories.58 61 One tool 
generated additional questions based on patients’ responses or severity grading.59 
In all cases, symptom reports were generated for clinicians to review, some providing  graphical 
overviews,57 58 60 61 one ranking  summarised symptoms in order of support need.59 Notably, ‘Choice 
Interactive Tailored Patient Assessment’ (Choice ITPA) was used across intervention and control 
groups, with clinician review of symptom reports the intervention feature under evaluation.59  
All symptom monitoring tools were clinically integrated (figure 2), though to varying extents. Some 
applied several approaches, whether encouraging patients to discuss symptoms at their next clinical 
encounter,58-60 making reports available for clinicians to review54 58-61 or using pre-defined thresholds 
to trigger alerts to clinicians, prompting urgent review outside of scheduled follow-up.55 56 Several 
emphasised  supporting59 or ‘coaching’ patients to communicate symptoms with their clinician.58 60 
One tool stands out as being designed specifically for hospitalized patients.57 
 
Communication conduits  
 
Three interventions represented channels of communication for patients at home, providing 
predominantly psychosocial support by connecting them to experts or peers.62-64 Two were advanced 
stage focused, 63 64 whilst the third targeted all stages of breast cancer.62 
One study trialled the provision of individually tailored psychosocial counselling to patients with breast 
cancer, based on cognitive behavioural, rational emotive and solution-focused therapy, via email 
correspondence with a clinical psychologist.62 Another had a dual physical and psychosocial focus 
(S/PS), providing tailored symptom management education and support through online message 
boards. This interactive platform facilitated communication and shared decision making between 
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patients and nurses.64 The final intervention evaluated an unmoderated online support group which 
encouraged self-facilitation of peer support in women with metastatic breast cancer.63  
A key feature of these interventions was the rapidity of support. Two were guided by health 
professionals, providing responses to patients within 24 hours, whilst remaining separate to the care 
pathway.62 64 The patient-led social networking intervention, in contrast, was purely self-management, 
encouraging users to seek support through shared experiences.63  
 
Information websites  
 
Three studies evaluated the delivery of supportive information via websites of varying formats, 
targeting all cancer stages .65-67 These supported physical66 or psychosocial65 aspects of health (S/PS); 
one encompassed both.67  
One intervention involved patients’ self-design of a personal website within a workshop setting, with 
a template comprising a blog, signposting, message board and ‘how you can help’ visitor information 
features.65 Another used a diagrammatic format to present information relating to the care pathway 
of patients with breast cancer, with built-in signposting links.66 The final website brought together 
patients’ experiences of living with colorectal cancer, organised as themes and case studies.67  
All three websites were self-management tools, delivered separately to patients’ care pathway, 
without features for accessing expert support. 
 
Efficacy relating to QoL and psychosocial domains  
 
Considerable variation was observed within and across intervention subtypes in the QoL and 
psychosocial measures applied, as well as the methods used to evaluate these constructs. We were 
therefore unable to draw definitive conclusions regarding efficacy. However, the use of these 
measures, and indications of efficacy between and within studies, was explored.  
Overall, 78% (29/37) of studies demonstrated efficacy, to varying degrees, through measures of QoL 
and related psychosocial constructs. These represented a primary outcome for 25 of the studies (four 
capturing them as primary and secondary outcomes), the remaining 12 capturing them as secondary 
outcomes alone. The studies which did not evidence efficacy in these areas (n=8) all reported 
limitations relating to small sample sizes and low statistical power.  
16 
 
Tables 2 & 3 provide an overview of the QoL and psychosocial outcome measures applied, their 
abbreviations and the constructs captured.    
 


































































































Quality of Life (QoL)/ 
Health Related Quality of 
life (HRQOL)31, 33, 34, 38, 43, 




- European Organisation for the Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) 
- EuroQol 5-Dimensions (EQ-5D) 
- Functional Assessment of Cancer Therapy – General (FACT-G) 
- Short Form Health survey (SF-12, SF-36) 
- World Health Organisation Quality of Life abbreviated 
scale (WHOQOL-BREF) 
- 15-dimensional instrument for assessing HRQOL (15D) 
Cancer site specific QoL40, 




- EORTC-BN20 (Brain tumour module) 
- EORTC-QLQ-BR23 (Breast cancer module) 
- Functional Assessment of Cancer Therapy - Breast (FACT-B) 
- Functional Assessment of Cancer Therapy – Lung (FACT-L) 























- European Organisation for the Research and Treatment of Cancer 
Quality of Life Questionnaire – CIPN20 (EORTC QLQ-CIPN20) 
Fatigue31, 37, 42, 48-51, 58 - Brief Fatigue Inventory (BFI) 
- Checklist Individual Strength (CIS) 
- Fatigue Symptom Inventory (FSI) 
- Functional Assessment of Chronic Illness Therapy - 
Fatigue (FACIT-F) 
- Functional Assessment of Cancer Therapy-Fatigue (FACT-Fatigue) 
- Multi-dimensional Fatigue Symptom Inventory - Short Form 
(MFSI- SF) 
- Profile of Moods States – Short Form (POMS-SF) 
Insomnia42, 48 - Insomnia Severity Index (ISI) 
- Women's Health Initiative Insomnia Rating Scale (WHIIRS) 
Symptom distress32, 33, 38, 39, 
41, 54, 59, 60, 64  
- Edmonton Symptom Assessment Scale (ESAS) 
- Memorial Symptom Assessment Scale (MSAS-SF) 
- MD Anderson Symptom Inventory (MDASI) 
- Modified Edmonton Symptom Assessment Scale (ESAS)† 
- Symptom Distress Scale (SDS-15, SDS-22) 
- Symptom Representational Questionnaire (SRQ) 




- Symptom Representational Questionnaire (SRQ) 
Performance status/level 
of daily activity33, 63 
- Eastern Co-operative Oncology Group (ECOG) Performance Status 
Scale 













































































- Outcomes questionnaire (OQ-45) 
 
Depression31, 34, 37-39, 41-44, 51, 58, 65 
Depressed mood36 
Mood48  
- Beck Depression Inventory (BDI) 
- Centre for Epidemiologic Studies Depression Scale (CES-D) 
- Hospital Anxiety and Depression Scale (HADS-D) 
- Patient Health Questionnaire (PHQ-8, PHQ-9) 
- Patient-Reported Outcomes Measurement Information 
System (PROMIS) – Depression item bank 
- Profile of Moods States – Short Form (POMS-SF) 
Stress50 - Calgary Symptoms of Stress Inventory (CSOSI) 
Anxiety/anxious mood34, 36, 37, 39, 
41, 43, 50, 66  
- Hospital Anxiety and Depression Scale (HADS-A) 
- Impact of Events Scale – Revised (IES-R) 
- Profile of Moods States – Short Form (POMS-SF) 
- Spielberger State-Trait Anxiety Inventory (STAI)  
Anger/angry mood36, 50 - Profile of Moods States – Short Form (POMS-SF) 
Positive/negative affect45, 63 - Negative Mood Regulation Scale (NMR) 
- Positive and Negative Affect Scale (PANAS) 
Positive mental health46 - Mental Health Continuum – Short Form 
Feelings over past week65 - Profile of Moods States – Short Form (POMS-SF) 
Cancer related intrusive 
thoughts & feelings/post- 
traumatic symptoms45, 65  
Rumination46 
Fear of cancer recurrence46 
- Fear of Cancer Recurrence Inventory (FCRI) 
- Impact of Events Scale – Revised (IES-R) 
- Posttraumatic Growth Inventory (PTGI) 
- Rumination and Reflection Questionnaire (RRQ) 
Confusion50 - Profile of Moods States (POMS) 
Psychological distress35, 37, 46, 
49, 57, 62 
 
Cancer related distress44 
 
- Brief Symptom Inventory (BSI) 
- Distress Thermometer (DT) 
- Hospital Anxiety and Depression Scale (HADS) 
- Impact of Events Scale (IES)/Impact of Events Scale-Revised 
(IES-R) 
- Patient Health Questionnaire (PHQ-4) 
Self-efficacy for coping with 
cancer38, 39, 41, 45, 67  
- Cancer Behaviour Inventory (CBI)/CBI-B (Brief version) 
- Stanford Inventory of Cancer Patient Adjustment (SICPA) 
Vigour/positive mood37, 50, 65 - Profile of Moods States (POMS, POMS-SF) 
Spirituality50 
Peace/meaning36 
Appreciation of life65 
- Functional Assessment of Chronic Illness therapy - 
Spiritual well- being (FACIT-Sp)  
- Posttraumatic Growth Inventory (PTGI) 
Mindfulness46, 50, 53 - Five Facet Mindfulness Questionnaire (FFMQ) 
- Mindful Attention Awareness Scale (MAAS) 
Mental adjustment62 - Mental Adjustment to Cancer (MAC) scale 
Perception of positive 
changes after adversity50, 65 
Relating to others65 
- Posttraumatic Growth Inventory (PTGI) 
Social & functional well-being45 - Functional Assessment of Cancer Therapy – Breast (FACT-B) 
Social support38, 40, 41 - Medical Outcomes Study Social Support Survey (MOS-SS) 
- Multi-dimensional Scale of Perceived Social Support (MSPSS) 




Interactive health communication applications  
 
Most IHCAs (11/12) demonstrated measurable improvements, to  varying extents, in QoL and 
psychosocial constructs. These spanned the range of delivery modes (figure 2) and comprised vastly 
differing content (PS, S and H/L).  
Five interventions demonstrated significant efficacy (p≤0.05) through direct measurement of QoL 
using FACT-G, FACT-B, WHOQOL-BREF and EORTC-QLQ-C30.31 33 34 40 41 As well as supporting QoL, one 
intervention also resulted in less worsening of self-efficacy for users (following initiation of 
chemotherapy) compared to controls (p=0.03).41 Another led to improvements in QoL alongside 
emotional function (p<0.01) and symptom distress (p<0.01).33 Each of these interventions included 
features for symptom self-management, four also integrating some form of expert support.31 33 40 41   
In the absence of direct QoL measurement, other IHCAs were found to support or improve diverse 
related constructs such as symptom distress, anxiety, depression and peace. Their content was equally 
diverse. Two were purely self-management,36 39 though both featured user-user communication, and 
one included expert support through clinical integration.32 For ‘mi Living Story’, an improved sense of 
peace was observed (p=0.029), alongside a ‘trend’ for improved depressed mood (p=0.097).36 Breast 
cancer patients using the ‘WebChoice’ intervention reported significant improvements in symptom 
distress (p=0.001), anxiety (p=0.03) and depression (p=0.03) compared to those receiving usual care.39 
However, use of the same intervention in patients with breast and prostate cancers, with the addition 
of expert support, demonstrated limited efficacy (though contrasting outcome measures prevent 
direct comparisons between studies).38 Use of the lung cancer (advanced stage) specific version of the 
‘Comprehensive Health Enhancement Support System’ (CHESS) by patient-caregiver dyads resulted in 
lower physical symptom distress (measured using a modified ESAS) compared to internet use.32 This 
was confined to measurements taken at 4 months (p=0.031) and 6 months (p=0.004) after initiating 
the intervention, however, and was not observed at earlier (2 months) or later (8 months) time points. 
The study evaluating the breast cancer specific version of CHESS40 (compared to both controls and use 
of the internet) captured improvements in QoL (FACT-B) and social support (using a 6-item scale 
developed in a previous study),68 this time confined to 4 months post-intervention (p=0.018 and 
p=0.021 respectively). Both versions included varying levels of expert support.   
Users of ‘Health Space’, an IHCA focusing on user-user engagement with expert input, experienced 
significant improvement in fatigue (measured as a subscale of POMS-SF) relative to controls (p=0.04). 
However,  improvements in other psychosocial domains (psychological functioning, depressive 
symptoms, anxiety and vigour) were not significant.37 Similarly, the professionally delivered ‘Surviving 
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and Thriving with Cancer’ showed marginal efficacy, measuring a range of psychosocial variables 
(fatigue, insomnia and depression) and finding significant reductions for intervention users in 
insomnia alone (p=0.03).42 The self-management ‘Together’ intervention also applied a range of 
psychological measures (HADS-A, DT and IES), though found no significant effects.35   
 
Virtual programmes of support  
 
Indications of QoL-related efficacy were also evident for diverse (predominantly PS) virtual 
programmes of support (9/11), delivered in numerous ways. 
Three studies evidenced significant improvements in QoL scores (measured using FACIT-F, FACT-B, 
EORTC-QLQ-C30 and  EORTC-QLQ-BR23),49 52 53 though programme content and delivery contrasted 
significantly. ‘Headspace’ delivered mindfulness training through self-management, improving scores 
for both QoL (p<0.01) and mindfulness (p=0.04).53 The others incorporated varying degrees of expert 
support.  A supported self-management programme for coping with stress improved QoL relating to 
fatigue (p=0.007), as well as reducing distress (p=0.03),49 and a professionally guided exercise (H/L) 
programme  led to significantly improved QoL (p<0.01).52  
Another online mindfulness programme, this time professionally delivered, assessed a host of 
psychosocial measures. These included total mood disturbance, stress, spirituality, post-traumatic 
growth (PTG) and mindfulness (captured using POMS, CSOSI, FACIT-Sp and FFMQ respectively). The 
study found significant improvements (p≤0.049), of moderate effect size, for all but PTG in 
intervention users versus controls.50  
Five studies reported less definitive evidence of QoL-related efficacy. For some professionally 
delivered programmes, trends for improved scores in  applied measures did not reach significance44 
or were confined to a specific subscale (e.g. mental health related QoL).46 The professionally-delivered 
online CBT stress management (CBSM) intervention did not lead to a statistically significant 
improvement in QoL. However, mean difference in FACT-G scores between groups met the threshold 
for clinical significance (defined as a minimum difference of 4 points for the total scale and 2 points 
for subscales).44 Whilst the electronic mindfulness-based cognitive therapy (eMBCT) improved mental 
health-related QoL, mindfulness skills and positive mental health, and reduced rumination and fear of 
recurrence (p<0.025), this was also true for the face-to-face equivalent, when compared to usual 
care.46 Supported self-management did not lead to improved QoL for the ‘Coping with Cancer 
Workbook’, yet users demonstrated significant improvement in self-efficacy (p=0.019) and cancer 
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related post-traumatic symptoms (p=0.002).45 Whilst participants trialling the self-management ‘Sleep 
Healthy Using The Internet’ (SHUTi) did not experience improvements in QoL, depression or anxiety, 
overall adjusted effect sizes for these constructs ranged from small to large (d=0.42-0.54).48 Lack of 
significance may in part be explained by the underpowered analysis of a relatively small sample. 
Intervention use was, however, associated with significant improvements in fatigue, assessed using 
the MSFI-SF (p<0.01).48 For the anxiety self-management mobile application, QoL, anxiety and 
depression improved for both intervention and control participants, yet there were no significant 
between group differences. Further analysis demonstrated efficacy for a distinct sub-group (severely 
anxious at baseline, p=0.010), though cautious interpretation is warranted due to small numbers.43 
Two programmes were unable to evidence QoL-related efficacy, though both were evaluated within 
underpowered studies. These applied SF-36 to assess health-related QoL (HRQOL) with use of guided 
online self-help51 and EORTC QLQ-CIPN20 to capture symptom-related QoL following online self-
guided CBT pain management.47 Notably, glioma patients using the online self-help (plus expert 
support) reported a post-treatment reduction in fatigue of borderline significance (p=0.054).51 
 
Symptom monitoring tools  
 
The symptom monitoring tools (all S and S/PS) demonstrated efficacy in 7/8 studies, across diverse 
QoL and psychosocial domains. Again, this was not confined to a particular style of intervention or 
mode of delivery. 
Tools which alerted clinicians to serious reported symptoms demonstrated significant improvement 
in QoL scores using FACT-L (p=0.04)55 and EuroQol EQ-5D (p=<0.001).56 However, indications of 
efficacy were also reported for less intensive symptom monitoring approaches. Completion of touch 
screen QoL questionnaires in clinic, with subsequent clinician review, improved FACT-G scores for 
intervention versus control participants (p=0.006), though there was no significant difference 
between intervention users and the attention-control group (QoL questionnaire completion without 
clinician feedback).61 For E-MOSAIC, direct integration of symptom reports completed in clinic did not 
result in a significant difference in global QoL (EORTC-QLQ-C30), though symptom distress (ESAS) was 
significantly less with intervention use (p=0.003).54  
Tools coaching patients to communicate their symptoms to their healthcare team resulted in variable 
outcomes. Patients using the ‘Communicating Health Assisted by Technology’ (CHAT) intervention 
experienced worsening HRQOL, measured using SF-36.58 Conversely, those using Choice ITPA were 
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significantly less distressed by their symptoms (specifically discomfort, eating/drinking, sleep/rest and 
sexuality, with significance set at p≤0.10) than control participants (Choice ITPA in absence of clinician 
review). Notably, the effect of Choice ITPA in comparison to care as usual (i.e. absence of symptom 
monitoring) was not assessed.59 
Indeed, symptom monitoring plus clinician feedback resulted in reductions in symptom distress 
(p=0.00354 and p=0.0260) and psychological distress (p=0.008)57 across other interventions measuring 
this construct, using the ESAS54 57 and the SDS-15.60 
 
Communication conduits  
 
The professionally guided (predominantly PS) communication conduits varied in efficacy. Participants 
receiving counselling via email experienced no significant improvement in distress or overall QoL, 
captured using the BSI and EORTC-QLQ-C30.62 For patients using the message board based 
intervention (S/PS), there was no evidence of impact on consequences or controllability of symptoms 
between groups.64 Yet, two weeks post intervention, users demonstrated significantly lower symptom 
distress (p=0.012), and a trend (though non-significant) for improved symptom severity, compared to  
controls  (p=0.058). However, this effect, observed using the SRQ, was not maintained at six weeks.64 
For the self-management peer-peer online support group, completion of QoL measures (ECOG and 
FACT-B) evidenced little difference between study arms, though definitive conclusions regarding 




Within the studies evaluating self-management information websites, 2/3 did not demonstrate 
significant intervention effects in QoL-related outcomes (measured using the Quality of Life 
Instrument - Breast Cancer Patient Version,66 the SAI66 and the CBI-B67).  
However, after six months, users creating their own personal (PS) website within a workshop setting 
(‘Project Connect Online’, which is likely to have involved some expert support), experienced 
significant improvements  in broader psychosocial outcomes of depressive symptoms (p=0.009), 






This systematic review has identified a broad range of web and technological interventions delivering 
cancer support to patients living with advanced cancer. Based on shared features and functionality, 
and in consultation with the wider literature, five distinct subtypes emerged: IHCAs, virtual 
programmes of support, symptom monitoring tools, communication conduits and information 
websites. Distinct approaches to delivering support were identified and described within the model 
of web and technological intervention delivery (figure 2). These ranged from independent or 
supported self-management, to interventions with elements of professional facilitation and those 
integrated with usual care. Clinical integration was mostly observed in the symptom monitoring tools, 
with health professional involvement encouraged or directly facilitated, whilst the information 
websites guided independent self-management. For the most part, interventions could be placed 
between these two extremes, encouraging self-management whilst offering varying degrees of expert 
support. This model, and the definitions and categorisations described, could be used as a framework 
to guide future intervention development.  
Interventions focussed on one or more of three key areas: psychosocial, symptom management and 
health & lifestyle. Psychosocial considerations were an overarching focus across the subtypes. For the 
virtual programmes of support, psychological behaviours or symptoms were targeted in almost all 
cases (10/11), most applying CBT techniques. Psychosocial needs were also a predominant focus for 
the IHCAs (11/12), incorporated through various forms of psychotherapy, psychoeducation or 
socioemotional support. The smaller number of information websites and communication conduits 
were also largely shaped by these considerations. Symptom monitoring tools, in contrast, mostly 
targeted patients’ physical health through supported management of symptoms and side-effects. An 
underlying link to psychosocial well-being was recognised, however, with 6/8 of these studies 
assessing QoL or psychosocial constructs as primary study outcomes. The past decade has seen a 
breadth of research emphasising the need for psychosocial considerations as a core aspect of the care 
and support of patients with cancer.69, 70 It is unsurprising, therefore, that such a large number of 
interventions are being developed with a focus on addressing these needs. However, whilst it is 
difficult to draw definitive conclusions, this review has highlighted wide-ranging efficacy across 
physical, psychosocial, and more general health & lifestyle support alike. A tendency for interventions 
to encompass patients across all stages of cancer makes it difficult to gauge their impact for those 
specifically in the advanced stages. Yet, these findings support research emphasising the sheer 
breadth of needs, often unmet, encountered right across the cancer trajectory.7 71 Whilst psychosocial 
care and support is fundamental, it is one aspect of what is described as a ‘spectrum’ of patient 
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needs.14 More complete support must also encompass the physical, functional and spiritual needs 
which collectively determine QoL.72 
Furthermore, what is most evident from the significant variation in efficacy between studies, 
interventions, patient populations and modes of delivery, is that a standardised ‘one size fits all’ 
template for cancer support does not exist. IHCAs, in contrast, offer the possibility of meeting multiple 
supportive needs in a multitude of ways. This flexibility may explain why they were the most widely 
evaluated of the interventions. Though their focus was largely psychosocial, they brought together a 
range of other support and offer the scope to tailor to specific patient groups. Self-management and 
self-care were encouraged through integrated features such as educational exercises, forums and 
decision-making tools, delivered with varying levels of expert guidance. Most conferred some level of 
psychosocial or QoL-related benefit for users, albeit to varying extents and across heterogeneous 
populations.  
Sheer complexity and variation within and across the intervention subtypes meant it was not possible 
to attribute efficacy in particular QoL/psychosocial domains to specific features or components.  The 
relationship between mode of delivery and specific outcomes appeared equally complex. However, a 
potential relationship between QoL-related efficacy more generally and features for expert or health 
professional support, of varying intensity, appeared evident. Though not always the case, this was 
observed in interventions offering supported self-management, professionally delivered support or 
clinical integration of support as part of patients’ usual care. Features for symptom monitoring and 
self-management were also frequently seen in interventions evidencing QoL-related efficacy. Indeed, 
these often incorporated some form of expert input, linking the two elements inextricably. However, 
the potential value of both is clear. Peer-peer communication, social networking or shared 
experiences were also features of multiple interventions evidencing QoL-related improvements. 
Whilst there is increasing emphasis on empowering patients with chronic diseases to self-manage and 
to have a central role in their care,6 these findings remind us of the value of collaboration and shared 
input, engaging the patient, professionals and peers. Indeed, this lessens the burden of disease 
management at both an individual and a service level.73 Crucially, the model of web and technological 
intervention delivery should not be seen as a hierarchy, rather as a group of potential approaches, any 
number of which may be harnessed to support diverse patient needs and preferences. This has been 
evidenced through widespread efficacy, with 78% of studies demonstrating  measurable improvement 
in QoL and/or psychosocial well-being. Whilst this evidence guides us in supporting patients with 
cancer more generally, future interventions must target those with advanced cancer more specifically. 
This may be achieved through greater emphasis on patient and public involvement (PPI), integrating 
lived experiences in aspects of intervention development and evaluation. Indeed, Corbett et al 
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emphasised the potential value of patient involvement in intervention design, to ensure challenges 
specific to their stage of the cancer trajectory are addressed in a way which is both useful and 
acceptable.17 Beyond the development phase, greater representation of patients with advanced 
cancer within larger scale intervention trials will strengthen the evidence base guiding their support. 
 
Study limitations  
 
Whilst this review aimed to evaluate support for those living with advanced cancer, just 13 of the 37 
studies specifically targeted these patients.  Across mixed populations, representation of advanced 
stage cancers was variable. Given the significant heterogeneity of study populations, it is hard to 
distinguish what works well for those with advanced cancer. 
Further heterogeneity, related to interventions, study methods and outcome measures, meant  we 
were unable to quantitatively determine intervention efficacy through meta-analysis. It was also 
difficult to ascertain whether studies were sufficiently powered to detect changes in the outcomes of 
interest, since this was not  always reported for QoL and psychosocial measures. As risk of bias varied 
significantly across studies, with judgement limited by inadequate reporting, findings must also be 
interpreted cautiously.  
Due to limited time and resources, data extraction and risk of bias assessment were performed by one 
reviewer (K.K). Furthermore, as indicated by the high proportion of recent publications, this field is 





The evolving chronicity of cancer has significant implications on cancer services, not only in terms of 
growing demand but also in relation to changing patient needs. The internet and technology offer the 
possibility for more cost-effective, tailored and accessible monitoring and support, reducing the 
burden of follow-up on healthcare services and patients alike.14 74 This review has identified a breadth 
of web and technological interventions designed to support patients across the cancer trajectory,  the 
vast majority evidencing some degree of efficacy relating to QoL and psychosocial well-being. 
However, there is a pressing need for these innovations to more exclusively tailor their design and 
target their evaluation to the increasing number of patients living with advanced cancer. Involving 
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these patients in the development and larger-scale evaluation of future multi-faceted supportive 
interventions may ensure that their complex supportive needs are more holistically addressed. As 
cancer treatments continue to progress, so too should the evidence guiding us in how best to support 
the many patients who will, as a direct result, live longer in the advanced stages of disease.  
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Figure 1: PRIMSA flow diagram of study selection.  
Figure 2: Model of web & technological intervention delivery. 
 
 
